National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States
- 18 April 2016
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (18) , 5107-5112
Abstract
Significance: Vaccination protects against human papilloma virus (HPV)-induced cervical cancer, but coverage varies markedly across the United States. The nonavalent vaccine produces greater health benefits than the bivalent and quadrivalent vaccines at a lower societal cost. Because of the impact of herd immunity, any expansion in coverage will be much more effective in reducing cancer incidence and healthcare costs if targeted in those states with the lowest coverage. Because of interstate migration and the long duration between HPV infection and resultant cervical cancer, much of the benefit of vaccination will be realized beyond a state’s borders. Therefore, both cervical cancer incidence and expenditure can be substantially reduced if the states coordinate policies to promote expansion of coverage, particularly for the new nonavalent vaccine.Keywords
Funding Information
- HHS | National Institutes of Health (2 U01 GM087719)
- HHS | National Institutes of Health (5 U01 GM105627)
- Gouvernement du Canada | Canadian Institutes of Health Research (450024)
- James S. McDonnell Foundation (220020114)
This publication has 64 references indexed in Scilit:
- Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical CancerVaccine, 2012
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical DiseaseThe Journal of Infectious Diseases, 2011
- Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort studyThe Lancet, 2011
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in MalesNew England Journal of Medicine, 2011
- Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of InfectionJNCI: Journal of the National Cancer Institute, 2010
- Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆Gynecologic Oncology, 2009
- Health and Economic Implications of HPV Vaccination in the United StatesNew England Journal of Medicine, 2008
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006